Skip to content

PRObiotics and SYNbiotics in infants in Kenya; the PROSYNK study

PRObiotics and SYNbiotics in infants in Kenya; the PROSYNK study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
PACTR
Registry ID
PACTR202003893276712
Enrollment
600
Registered
2020-03-02
Start date
2020-05-11
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Nutritional, Metabolic, Endocrine Paediatrics

Interventions

Lab4b synbiotic
Lab4b probiotic

Sponsors

Liverpool School of Tropical Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: singleton newborn birthweight (BW) or current weight (if BW not known) ?2000g well infant who is breastfed and has taken at least one breast feed well lives within the catchment area of the research centre at Homa Bay Hospital informed consent secured from mother/carer

Exclusion criteria

Exclusion criteria: multiple pregnancy (e.g. twin/triplets) infant aged 4 days or older suspicion or presence of any acute illness (e.g. fever, receiving treatment with antibiotics) congenital abnormality that might be life-threatening or impair growth infant with potential contraindication to pre/synbiotics (e.g. suspected immune suppression; cardiac abnormality) mother unlikely to stay in study area for the duration of the study any health staff or study staff concerns regarding safety to participate in the trial

Design outcomes

Primary

MeasureTime frame
Plasma alpha-1-acid glycoprotein concentration

Secondary

MeasureTime frame
Biomarkers at ages 6 weeks and 3, 6 and 12 months 1. Stool biomarker of intestinal inflammation: Myeloperoxidase 2. Stool biomarker of increased intestinal permeability: a1-antitrypsin (AAT) 3. Plasma marker of chronic inflammation: alpha 1-Acid Glycoprotein at 6 weeks and 3 and 12 months 4. Plasma marker of acute inflammation: C-reactive protein (CRP) 5. Plasma marker of gut mucosal integrity: intestinal fatty acid binding protein (IFABP) 6. Plasma growth hormones: insulin-like growth factor (IGF)-1 and its carrier protein IGF binding protein 3 7. Stool pH Clinical outcomes to age 2 years 1. Mortality 2. Episodes of hospital admission 3. Episodes of all-cause sick-child clinic visits 4. Episodes of disease-specific sick-child clinic visits (e.g. diarrhoea; respiratory and skin infections) 5. Anthropometric outcomes: weight, length, mid-upper arm circumference (MUAC), head circumference Other outcomes 1. Feeding and WASH practices and environmental factors that likely influence the development of the gut microbiome assessed by questionnaires 2. Cognitive development assessed at 24 months

Countries

Kenya

Contacts

Public ContactIwaret Otiti

Study Manager

Iwaret.Otiti@lstmed.ac.uk+254724007076

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 12, 2026